Получение и исследование свойств рекомбинантных фрагментов антитела, специфичного к сердечной изоформе тропонина I

Список литературы

1. Hagemeyer С.Е., von Zur Muhlen С., von Elverfeldt D., and Peter K. Single-chain antibodies as diagnostic tools and therapeutic agents. Thromb. Haemost., 2009. 101(6): p. 1012−1019.
2. Filatov V.L., Katrukha A.G., Bulargina T.V., and Gusev N.B. Troponin: structure, properties, and mechanism of functioning. Biochemistry, 1999. 64(9): p. 969−985.
3. Cummins В., Auckland M.L., and Cummins P. Cardiac-specific troponin-I radioimmunoassay in the diagnosis of acute myocardial infarction. Am. Heart J., 1987. 113(6): p. 1333−1344.
4. Ilva Т., Lund J., Porela P., Mustonen H., Voipio-Pulkki L.M., Eriksson S., Pettersson K., Tanner P., and Pulkki K. Early markers of myocardial injury: cTnl is enough. Clin. Chim. Acta, 2009.400(1−2): p. 82−85.
5. Sundberg E.J. Structural basis of antibody-antigen interactions. Methods Mol. Biol., 2009. 524: p. 23−36.
6. Thygesen K., Alpert J.S., Jaffe A.S., Simoons M.L., Chaitman B.R., and White H.D. Third Universal Definition of Myocardial Infarction. Circulation, 2012.126(16): p. 2020−2035.
7. Apple F.S. and Collinson P.O. Analytical characteristics of high-sensitivity cardiac troponin assays. Clin. Chem., 2012. 58(1): p. 54−61.
8. Tate J.R., Bunk D.M., Christenson R.H., Katrukha A., Noble J.E., Porter R.A., Schimmel H., Wang L., and Panteghini M. Standardisation of cardiac troponin I measurement: past and present. Pathology (Phila). 2010. 42(5): p. 402−408.
9. Ylikotila J., Hellstrom J.L., Eriksson S., Vehniainen M., Valimaa L., Takalo H., Bereznikova A., and Pettersson K. Utilization of recombinant Fab fragments in a cTnl immunoassay conducted in spot wells. Clin. Biochem., 2006. 39(8): p. 843−850.
10. Ylikotila J. (2009) Highly functional binding surface for miniaturised solid-phase immunoassays. A spot story. URL: http://www.doria.fi/handle/10 024/43773.
11. Saul F.A. and Alzari P.M. Crystallographic studies of antigen-antibody interactions. Methods Mol. Biol, 1996. 66: p. 11−23.
12. Katrukha A., Bereznikova A., Filatov V., and Esakova T. Biochemical factors influencing measurement of cardiac troponin I in serum. Clin. Chem. Lab. Med., 1999. 37(11−12): p. 1091−1095.
13. Eriksson S., Halenius H., Pulkki K., Hellman J., and Pettersson K. Negative interference in cardiac troponin I immunoassays by circulating troponin autoantibodies. Clin. Chem., 2005. 51(5): p. 839−847.
14. Schroeder H.W., Jr. and Cavacini L. Structure and function of immunoglobulins. J. Allergy Clin. Immunol., 2010. 125(2 Suppl 2): p. S41−52.
15. Volkov V., Kayushina R., Lapuk V., Shtykova E., Varlamova E., Malfois M., and Svergun D. Solution structures of human immunoglobulins IgG and IgM and rheumatoid factor IgM-RF. Crystallography Reports, 2003.48(1): p. 98−105.
16. Padlan E.A. Anatomy of the antibody molecule. Mol. Immunol, 1994. 31(3): p. 169−217.
17. Sundberg E.J. Structural basis of antibody-antigen interactions. Methods Mol Biol, 2009. 524: p. 23−36.
18. Kashmiri S.V., De Pascalis R., Gonzales N.R., and Schlom J. SDR grafting—a new approach to antibody humanization. Methods, 2005. 36(1): p. 25−34.
19. Padlan E.A., Abergel C., and Tipper J.P. Identification of specificity-determining residues in antibodies. FASEBJ., 1995. 9(1): p. 133−139.25,26,27,28,29,30,31,32,33,34,35,36,
20. Raghavan M. and Bjorkman P.J. Fc receptors and their interactions with immunoglobulins. Annu. Rev. Cell Dev. Biol., 1996. 12: p. 181−220.
21. Jung D., Giallourakis C., Mostoslavsky R., and Alt F.W. Mechanism and control of V (D)J recombination at the immunoglobulin heavy chain locus. Annu. Rev. Immunol., 2006. 24: p. 541−570.
22. Chowdhury P. S. Engineering hot spots for affinity enhancement of antibodies. Methods Mol. Biol., 2003. 207: p. 179−196.
23. Ho M. and Pastan I. In vitro antibody affinity maturation targeting germline hotspots. Methods Mol. Biol., 2009. 525: p. 293−308, xiv.
24. Tomlinson I.M., Walter G., Jones P.T., Dear P.H., Sonnhammer E.L., and Winter G. The imprint of somatic hypermutation on the repertoire of human germline V genes. J. Mol. Biol., 1996. 256(5): p. 813−817.
25. Maynard J. and Georgiou G. Antibody engineering. Annu. Rev. Biomed. Eng., 2000. 2: p. 339−376.
26. Foote J. and Eisen H.N. Kinetic and affinity limits on antibodies produced during immune responses. Proc. Natl. Acad. Sci. U. S. A., 1995. 92(5): p. 1254−1256.
27. Batista F.D. and Neuberger M.S. Affinity dependence of the B cell response to antigen: a threshold, a ceiling, and the importance of off-rate. Immunity, 1998. 8(6): p. 751−759.
28. Cauerhff A., Goldbaum F.A., and Braden B.C. Structural mechanism for affinity maturation of an anti-lysozyme antibody. Proc. Natl. Acad. Sci. U. S. A., 2004. 101(10): p. 3539−3544.
29. Ho M., Kreitman R.J., Onda M., and Pastan I. In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. J. Biol. Chem., 2005. 280(1): p. 607−617.
30. Thorpe I.F. and Brooks C.L., 3rd Molecular evolution of affinity and flexibility in the immune system. Proc. Natl. Acad. Sci. U. S. A., 2007. 104(21): p. 8821−8826.
31. Davies D.R. and Padlan E.A. Twisting into shape. Curr. Biol., 1992.2(5): p. 254−256.
32. Braden B.C. and Poljak R.J. Structural features of the reactions between antibodies and protein antigens. FASEBJ., 1995. 9(1): p. 9−16.
33. Acierno J.P., Braden B.C., Klinke S., Goldbaum F.A., and Cauerhff A. Affinity maturation increases the stability and plasticity of the Fv domain of anti-protein antibodies. J. Mol. Biol, 2007. 374(1): p. 130−146.
34. Cowell L.G. and Kepler T.B. The nucleotide-replacement spectrum under somatic hypermutation exhibits microsequence dependence that is strand-symmetric and distinct from that under germline mutation. J. Immunol., 2000. 164(4): p. 1971−1976.
35. Li Y., Li H., Yang F., Smith-Gill S.J., and Mariuzza R.A. X-ray snapshots of the maturation of an antibody response to a protein antigen. Nat. Struct. Biol., 2003. 10(6): p. 482−488.J
36. Masuda K., Sakamoto K., Kojima M., Aburatani T., Ueda T., and Ueda H. The role of interface framework residues in determining antibody V (H)/V (L) interaction strength and antigen-binding affinity. FEBSJ., 2006.273(10): p. 2184−2194.
37. Wedemayer G.J., Patten P.A., Wang L.H., Schultz P.G., and Stevens R.C. Structural insights into the evolution of an antibody combining site. Science, 1997. 276(5319): p. 1665−1669.
38. Bartal A.H. and Hirshaut Y. Methods ofhybridoma formation. 1987: Humana Press.
39. Engvall E. and Perlmann P. Enzyme-linked immunosorbent assay (ELISA). Quantitative assay of immunoglobulin G. Immunochemistry, 1971. 8(9): p. 871−874.
40. Van Weeman B. and Schuurs A. Immunoassay using antigen-enzyme conjugates. FEBS Lett., 1971. 15: p. 232−235.
41. Towbin H., Staehelin T., and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc. Natl. Acad. Sci. U. S. A., 1979. 76(9): p. 4350−4354.
42. Katrukha A., Bereznikova A., and Pettersson K. New approach to standardisation of human cardiac troponin I (cTnl). Scand. J. Clin. Lab. Invest. Suppl., 1999. 230: p. 124−127.
43. Koshkina E.V., Krasnosel’skii M., Fedorovskii N.M., Goriacheva E.V., Polupan A.A., Arefev A.A., and Katrukha A.G. Diagnostic value of cardiac troponin T increase in critically ill patients. Anesteziol. Reanimatol., 2009(6): p. 42−46.
44. Adams J.E., 3rd, Bodor G.S., Davila-Roman V.G., Delmez J.A., Apple F.S., Ladenson J.H., and Jaffe A.S. Cardiac troponin I. A marker with high specificity for cardiac injury. Circulation, 1993. 88(1): p. 101−106.
45. Vaidya H.C. Myoglobin: an early biochemical marker for the diagnosis of acute myocardial infarction./. Clin. Immunoassay, 1994. 17(1): p. 35−39.
46. Filatov V.L., Katrukha A.G., Bereznikova A.V., Esakova T.V., Bulargina T.V., Kolosova O.V., Severin E.S., and Gusev N.B. Epitope mapping of anti-troponin I monoclonal antibodies. Biochem. Mol. Biol. Int., 1998.45(6): p. 1179−1187.
47. Krishnamurti U. and Steffes M.W. Glycohemoglobin: a primary predictor of the development or reversal of complications of diabetes mellitus. Clin. Chem., 2001. 47(7): p. 1157−1165.
48. Clark P.M. Assays for insulin, proinsulin (s) and C-peptide. Ann. Clin. Biochem., 1999. 36 (Pt 5): p. 541−564.
49. Ludwig J.A. and Weinstein J.N. Biomarkers in cancer staging, prognosis and treatment selection. Nat. Rev. Cancer, 2005. 5(11): p. 845−856.
50. Arthur J.M., Janech M.G., Varghese S.A., Almeida J.S., and Powell T.B. Diagnostic and prognostic biomarkers in acute renal failure. Contrib. Nephrol., 2008.160: p. 53−64.
51. Nakamura R.M. and Binder W.L. Current concepts and diagnostic evaluation of autoimmune disease. Arch. Pathol. Lab. Med., 1988.112(9): p. 869−877.
52. Ekins R. The free hormone hypothesis and measurement of free hormones. Clin. Chem., 1992. 38(7): p. 1289−1293.
53. Shivaraj G., Prakash B.D., Sonal V., Shruthi K., Vinayak H., and Avinash M. Thyroid function tests: a review. Eur. Rev. Med. Pharmacol. Sci., 2009.13(5): p. 341−349.
54. Cummings M.C., Lukehart S.A., Marra C., Smith B.L., Shaffer J., Demeo L.R., Castro C., and McCormack W.M. Comparison of methods for the detection of treponema pallidum in lesions of early syphilis. Sex. Transm. Dis., 1996.23(5): p. 366−369.
55. Stamm W.E., Cole B., Fennell C., Bonin P., Armstrong A.S., Herrmann J.E., and Holmes K.K. Antigen detection for the diagnosis of gonorrhea. J. Clin. Microbiol., 1984. 19(3): p. 399−403.
56. Black C.M. Current methods of laboratory diagnosis of Chlamydia trachomatis infections. Clin. Microbiol. Rev., 1997.10(1): p. 160−184.
57. Safford J.W., Abbott G.G., Craine M.C., and MacDonald R.G. Automated microparticle enzyme immunoassays for IgG and IgM antibodies to Toxoplasma gondii. J. Clin. Pathol., 1991. 44(3): p. 238−242.
58. Malomgre W. and Neumeister B. Recent and future trends in blood group typing. Anal. Bioanal. Chem., 2009. 393(5): p. 1443−1451.
59. Cole L.A. Human chorionic gonadotropin tests. Expert Rev. Mol. Diagn., 2009. 9(7): p. 721−747.
60. Donzeau M. and Knappik A. Recombinant monoclonal antibodies. Methods Mol. Biol., 2007. 378: p. 14−31.
61. Wark K.L. and Hudson P.J. Latest technologies for the enhancement of antibody affinity. Adv. Drug Deliv. Rev., 2006. 58(5−6): p. 657−670.
62. Hust M., Jostock T., Menzel C., Voedisch B., Mohr A., Brenneis M., Kirsch M.I., Meier D., and Dubel S. Single chain Fab (scFab) fragment. BMC Biotechnol., 2007. 7: p. 14.
63. Jain M., Kamal N., and Batra S.K. Engineering antibodies for clinical applications. Trends Biotechnol., 2007. 25(7): p. 307−316.
64. Chowdhury P. S. and Vasmatzis G. Engineering scFvs for improved stability. Methods Mol. Biol., 2003.207: p. 237−254.
65. Conrad U. and Scheller J. Considerations on antibody-phage display methodology. Comb. Chem. High Throughput Screen., 2005. 8(2): p. 117−126.
66. Telleman P. and Junghans R.P. The role of the Brambell receptor (FcRB) in liver: protection of endocytosed immunoglobulin G (IgG) from catabolism in hepatocytes rather than transport of IgG to bile. Immunology, 2000. 100(2): p. 245−251.
67. Lo B.K.C. ed. Antibody engineering. Methods and protocols. 2004, Humana Press.
68. Benhar I. and Pastan I. Cloning, expression and characterization of the Fv fragments of the anti-carbohydrate mAbs B1 and B5 as single-chain immunotoxins. Protein Eng., 1994. 7(12): p. 1509−1515.
69. Wlad H., Ballagi A., Bouakaz L., Gu Z., and Janson J.C. Rapid two-step purification of a recombinant mouse Fab fragment expressed in Escherichia coli. Protein Expr. Purif., 2001. 22(2): p. 325−329.
70. Saviranta P., Haavisto Т., Rappu P., Karp M., and Lovgren T. In vitro enzymatic biotinylation of recombinant fab fragments through a peptide acceptor tail. Bioconjug. Chem., 1998. 9(6): p. 725−735.
71. Presta L.G. Selection, design, and engineering of therapeutic antibodies. J. Allergy Clin. Immunol., 2005. 116(4): p. 731−736- quiz 737.
72. Winter G., Griffiths A.D., Hawkins R.E., and Hoogenboom H.R. Making antibodies by phage display technology. Annu. Rev. Immunol., 1994. 12: p. 433−455.
73. Smith G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science, 1985. 228(4705): p. 1315−1317.
74. Hanes J. and Pluckthun A. In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. U. S. A., 1997. 94(10): p. 4937−4942.
75. Liu R., Barrick J., Szostak J.W., and Roberts R.W. Optimized synthesis of RNA-protein fusions for in vitro protein selection. Methods Enzymol., 2000. 1(317): p. 268−293.
76. Daugherty P. S., Chen G., Olsen M.J., Iverson B.L., and Georgiou G. Antibody affinity maturation using bacterial surface display. Protein Eng., 1998. 11(9): p. 825−832.
77. Boder E.T., Midelfort K.S., and Wittrup K.D. Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity. Proc. Natl. Acad. Sci. U. S. A., 2000. 97(20): p. 10 701−10 705.
78. Boder E.T. and Wittrup K.D. Optimal screening of surface-displayed polypeptide libraries. Biotechnol. Prog., 1998.14(1): p. 55−62.
79. Boder E.T. and Wittrup K.D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol., 1997.15(6): p. 553−557.
80. Siegel R.W. Antibody affinity optimization using yeast cell surface display. Methods Mol. Biol., 2009. 504: p. 351−383.
81. Odegrip R., Coomber D., Eldridge B., Hederer R., Kuhlman P.A., Ullman C., FitzGerald K., and McGregor D. CIS display: In vitro selection of peptides from libraries of proteinDNA complexes. Proc. Natl. Acad. Sci. U. S. A., 2004. 101(9): p. 2806−2810.
82. Brockmann E.C. (2010) Evolution of Bioaffinity Reagents by Phage Display. URL: http://www.doria.fi/handle/10 024/62387.
83. Hoogenboom H.R. and Chames P. Natural and designer binding sites made by phage display technology. Immunol. Today, 2000. 21(8): p. 371−378.
84. Barderas R., Desmet J., Timmerman P., Meloen R., and Casal J.I. Affinity maturation of antibodies assisted by in silico modeling. Proc. Natl. Acad. Sci. U. S. A., 2008. 105(26): p. 9029−9034.
85. Pluckthun A., Schaffitzel C., Hanes J., and Jermutus L. In vitro selection and evolution of proteins. Adv. Protein Chem., 2000. 55: p. 367−403.
86. Hanes J., Schaffitzel C., Knappik A., and Pluckthun A. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol., 2000. 18(12): p. 1287−1292.
87. Tabuchi I., Soramoto S., Nemoto N., and Husimi Y. An in vitro DNA virus for in vitro protein evolution. FEBSLett., 2001. 508(3): p. 309−312.
88. Matsuura T. and Yomo T. In vitro evolution of proteins. J. Biosci. Bioeng., 2006. 101(6): p. 449−456.
89. Ulrich H.D., Patten P.A., Yang P.L., Romesberg F.E., and Schultz P.G. Expression studies of catalytic antibodies. Proc. Natl Acad. Sci. U. S. A., 1995. 92(25): p. 11 907−11 911.
90. Levin A.M. and Weiss G.A. Optimizing the affinity and specificity of proteins with molecular display. Mol Biosyst., 2006.2(1): p. 49−57.
91. Hawkins R.E., Russell S.J., and Winter G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J. Mol. Biol, 1992. 226(3): p. 889−896.
92. Yang W.P., Green K., Pinz-Sweeney S., Briones A.T., Burton D.R., and Barbas C.F., 3rd CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J. Mol Biol, 1995. 254(3): p. 392−403.
93. Verma R., Boleti E., and George A.J. Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems. J. Immunol. Methods, 1998. 216(1−2): p. 165−181.
94. Dimitrov D.S. and Marks J.D. Therapeutic antibodies: current state and future trends—is a paradigm change coming soon? Methods Mol Biol, 2009. 525: p. 1−27, xiii.
95. Dubel S. Recombinant therapeutic antibodies. Appl. Microbiol Biotechnol, 2007. 74(4): p. 723−729.
96. Stemmer W.P.C. Searching sequence space. Nat. Biotechnol., 1995. 13(6): p. 549−553.
97. Honegger A. Trobleshooting antibody fragments. 2003- Available from: http://www.bioc.uzh.ch/antibodv/IntroductionA^irtualSeminars/AE2003/source/slide01 .ht m.
98. Lippow S.M., Wittrup K.D., and Tidor B. Computational design of antibody-affinity improvement beyond in vivo maturation. Nat. Biotechnol., 2007. 25(10): p. 1171−1176.
99. Crameri A., Raillard S.A., Bermudez E., and Stemmer W.P. DNA shuffling of a family of genes from diverse species accelerates directed evolution. Nature, 1998. 391(6664): p. 288−291.
100. Stemmer W.P. Rapid evolution of a protein in vitro by DNA shuffling. Nature, 1994. 370(6488): p. 389−391.
101. Cline J., Braman J.C., and Hogrefe H.H. PCR fidelity of pfu DNA polymerase and other thermostable DNA polymerases. Nucleic Acids Res., 1996. 24(18): p. 3546−3551.
102. Martineau P. Error-prone polymerase chain reaction for modification of scFvs. Methods Mol. Biol., 2002. 178: p. 287−294.
103. Fujii I. Antibody affinity maturation by random mutagenesis. Methods Mol. Biol., 2004. 248: p. 345−359.
104. Low N.M., Holliger P.H., and Winter G. Mimicking somatic hypermutation: affinity maturation of antibodies displayed on bacteriophage using a bacterial mutator strain. J. Mol. Biol., 1996. 260(3): p. 359−368.
105. Greener A., Callahan M., and Jerpseth B. An efficient random mutagenesis technique using an E. coli mutator strain. Methods Mol. Biol., 1996. 57: p. 375−385.
106. Irving R.A., Kortt A.A., and Hudson P.J. Affinity maturation of recombinant antibodies using E. coli mutator cells. Immunotechnology, 1996. 2(2): p. 127−143.
107. Lantto J., Jirholt P., Barrios Y., and Ohlin M. Chain shuffling to modify properties of recombinant immunoglobulins. Methods Mol. Biol., 2002.178: p. 303−316.
108. Бикбулатова C.M., Мингазетдинова C.P., Чемерис A.B., and Вахитов B.A. Эволюция in vitro есть ли предел методам «перетасовки» генов? Успехи современной биологии, 2009. 129(4): р. 323−335.
109. Pogulis R.J., Vallejo A.N., and Pease L.R. In vitro recombination and mutagenesis by overlap extension PCR. Methods Mol. Biol., 1996. 57: p. 167−176.
110. Zhao H., Giver L., Shao Z., Affholter J .A., and Arnold F.H. Molecular evolution by staggered extension process (StEP) in vitro recombination. Nat. Biotechnol., 1998. 16(3): p. 258−261.
111. Sivasubramanian A., Sircar A., Chaudhury S., and Gray J.J. Toward high-resolution homology modeling of antibody Fv regions and application to antibody-antigen docking. Proteins, 2009. 74(2): p. 497−514.
112. Essen L.O. and Skerra A. The de novo design of an antibody combining site. Crystallographic analysis of the VL domain confirms the structural model. J. Mol. Biol., 1994. 238(2): p. 226−244.
113. Schiweck W. and Skerra A. Fermenter production of an artificial fab fragment, rationally designed for the antigen cystatin, and its optimized crystallization through constant domain shuffling. Proteins, 1995. 23(4): p. 561−565.
114. Marvin J.S. and Zhu Z. Computation-based design and engineering of protein and antibody therapeutics. Drug Design Reviews Online, 2005. 2(6): p. 419−425.
115. Teng S., Michonova-Alexova E., and Alexov E. Approaches and resources for prediction of the effects of non-synonymous single nucleotide polymorphism on protein function and interactions. Curr. Pharm. Biotechnol., 2008. 9(2): p. 123−133.
116. Yue P., Li Z., and Moult J. Loss of protein structure stability as a major causative factor in monogenic disease. J. Mol. Biol., 2005. 353(2): p. 459−473.
117. Ng P.C. and Henikoff S. SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res., 2003. 31(13): p. 3812−3814.
118. Раменский В. and Сюняев Ш. Вычислительный полиморфизм генома человека. Молекулярная биология, 2009.43(2): р. 286−294.
119. Sunyaev S., Ramensky V., and Bork P. Towards a structural basis of human non-synonymous single nucleotide polymorphisms. Trends Genet., 2000. 16(5): p. 198−200.
120. Sunyaev S., Ramensky V., Koch I., Lathe W., 3rd, Kondrashov A.S., and Bork P. Prediction of deleterious human alleles. Hum. Mol. Genet., 2001. 10(6): p. 591−597.
121. Ramensky V., Bork P., and Sunyaev S. Human non-synonymous SNPs: server and survey. Nucleic Acids Res., 2002. 30(17): p. 3894−3900.
122. Bromberg Y. and Rost B. SNAP: predict effect of non-synonymous polymorphisms on function. Nucleic Acids Res., 2007. 35(11): p. 3823−3835.
123. Teng S., Madej Т., Panchenko A., and Alexov E. Modeling effects of human single nucleotide polymorphisms on protein-protein interactions. Biophys. J., 2009. 96(6): p. 2178−2188.
124. Boas F.E. and Harbury P.B. Design of protein-ligand binding based on the molecular-mechanics energy model. J. Mol. Biol., 2008. 380(2): p. 415−424.
125. Reumers J., Schymkowitz J., Ferkinghoff-Borg J., Stricher F., Serrano L., and Rousseau F. SNPeffect: a database mapping molecular phenotypic effects of human non-synonymous coding SNPs. Nucleic Acids Res, 2005. 33(Database issue): p. D527−532.
126. Karchin R., Diekhans M., Kelly L., Thomas D.J., Pieper U., Eswar N., Haussler D., and Sali A. LS-SNP: large-scale annotation of coding non-synonymous SNPs based on multiple information sources. Bioinformatics, 2005.21(12): p. 2814−2820.
127. Capriotti E., Fariselli P., and Casadio R. I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res., 2005. 33(Web Server issue): p. W306−310.
128. Chowdhury P. S. Targeting random mutations to hotspots in antibody variable domains for affinity improvement. Methods Mol. Biol., 2002.178: p. 269−285.
129. Yau K.Y., Dubuc G., Li S., Hirama Т., Mackenzie C.R., Jermutus L., Hall J.C., and Tanha J. Affinity maturation of a V (H)H by mutational hotspot randomization. J. Immunol. Methods, 2005.297(1−2): p. 213−224.
130. Chowdhury P. S. and Pastan I. Improving antibody affinity by mimicking somatic hypermutation in vitro. Nat. Biotechnol., 1999. 17(6): p. 568−572.
131. Marvin J.S. and Lowman H.B. Redesigning an antibody fragment for faster association with its antigen. Biochemistry, 2003. 42(23): p. 7077−7083.
132. Selzer Т., Albeck S., and Schreiber G. Rational design of faster associating and tighter binding protein complexes. Nat. Struct. Biol., 2000. 7(7): p. 537−541.
133. Чугунов A. (2007) Новые успехи в предсказании пространственной структуры белков. URL: http://biomolecula.ru/content/l 89.
134. Чугунов А. (2008) Торжество компьютерных методов: предсказание строения белков. URL: http://biomolecula.ru/content/264.
135. Guo J.T., Ellrott К., and Xu Y. A historical perspective of template-based protein structure prediction. Methods Mol. Biol., 2008.413: p. 3−42.
136. Xu J., Jiao F., and Yu L. Protein structure prediction using threading. Methods Mol. Biol., 2008. 413: p. 91−121.
137. Eswar N., Webb В., Marti-Renom M.A., Madhusudhan M.S., Eramian D., Shen M.Y., Pieper U., and Sali A. Comparative protein structure modeling using Modeller. Curr. Protoc. Bioinformatics, 2006. Chapter 5: p. Unit 5 6.
138. Schwede T., Kopp J., Guex N., and Peitsch M.C. SWISS-MODEL: An automated protein homology-modeling server. Nucleic Acids Res., 2003. 31(13): p. 3381−3385.
139. Zhang Y. I-TASSER server for protein 3D structure prediction. BMC Bioinformatics, 2008.9: p. 40.
140. Bates P.A., Kelley L.A., MacCallum R.M., and Sternberg M.J. Enhancement of protein modeling by human intervention in applying the automatic programs 3D-JIGSAW and 3D-PSSM. Proteins, 2001. Suppl 5: p. 39−46.
141. Lambert C., Leonard N., De Bolle X., and Depiereux E. ESyPred3D: Prediction of proteins 3D structures. Bioinformatics, 2002. 18(9): p. 1250−1256.
142. Kelley L.A. and Sternberg M.J. Protein structure prediction on the Web: a case study using the Phyre server. Nat. Protoc., 2009.4(3): p. 363−371.
143. Lund O., Frimand K., Gorodkin J., Bohr H., Bohr J., Hansen J., and Brunak S. Protein distance constraints predicted by neural networks and probability density functions. Protein Eng., 1997. 10(11): p. 1241−1248.
144. Qian B., Raman S., Das R., Bradley P., McCoy A.J., Read R.J., and Baker D. Highresolution structure prediction and the crystallographic phase problem. Nature, 2007. 450(7167): p. 259−264.
145. Zhang Y. and Skolnick J. Automated structure prediction of weakly homologous proteins on a genomic scale. Proc. Natl. Acad. Sci. U. S. A., 2004. 101(20): p. 7594−7599.
146. Martin A.C.R. and Allen J. Bioinformatics Tools for Antibody Engineering, in Handbook of Therapeutic Antibodies. 2007.
147. Wu T.T. and Kabat E.A. An analysis of the sequences of the variable regions of Bence Jones proteins and myeloma light chains and their implications for antibody complementarity. J. Exp. Med., 1970. 132(2): p. 211−250.
148. Kabat E.A., Wu T.T., Bilofsky H., Reid-Milner M., and Perry H. Sequences of Proteins of Immunological Interest. 1983, Washington, DC: Public Health Service, NIH.
149. Al-Lazikani B., Lesk A.M., and Chothia C. Standard conformations for the canonical structures of immunoglobulins. J. Mol. Biol., 1997. 273(4): p. 927−948.
150. Chothia C. and Lesk A.M. Canonical structures for the hypervariable regions of immunoglobulins. J. Mol. Biol., 1987.196(4): p. 901−917.
151. Chothia C" Lesk A.M., Tramontano A., Levitt M., Smith-Gill S.J., Air G" Sheriff S., Padlan E.A., Davies D., et al. Conformations of immunoglobulin hypervariable regions. Nature, 1989. 342(6252): p. 877−883.
152. Martin A.C., Cheetham J.C., and Rees A.R. Modeling antibody hypervariable loops: a combined algorithm. Proc. Natl. Acad. Sci. U. S. A., 1989. 86(23): p. 9268−9272.
153. Honegger A. and Pluckthun A. Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool. J. Mol. Biol, 2001. 309(3): p. 657−670.
154. MacCallum R.M., Martin A.C., and Thornton J.M. Antibody-antigen interactions: contact analysis and binding site topography. J. Mol. Biol, 1996.262(5): p. 732−745.
155. Bruccoleri R.E. Ab initio loop modeling and its application to homology modeling. Methods Mol. Biol, 2000. 143: p. 247−264.
156. Martin A.C., Cheetham J.C., and Rees A.R. Molecular modeling of antibody combining sites. Methods Enzymol., 1991. 203: p. 121−153.
157. Whitelegg N.R. and Rees A.R. WAM: an improved algorithm for modelling antibodies on the WEB. Protein Eng., 2000.13(12): p. 819−824.
158. Whitelegg N. and Rees A.R. Antibody variable regions: toward a unified modeling method. Methods Mol. Biol, 2004. 248: p. 51−91.
159. Marcatili P., Rosi A., and Tramontano A. PIGS: automatic prediction of antibody structures. Bioinformatics, 2008. 24(17): p. 1953−1954.
160. Sircar A., Kim E.T., and Gray J.J. RosettaAntibody: antibody variable region homology modeling server. Nucleic Acids Res., 2009. 37(Web Server issue): p. W474−479.
161. Wiehe K., Peterson M.W., Pierce B., Mintseris J., and Weng Z. Protein-protein docking: overview and performance analysis. Methods Mol. Biol, 2008.413: p. 283−314.
162. Comeau S.R., Gatchell D.W., Vajda S., and Camacho C.J. ClusPro: an automated docking and discrimination method for the prediction of protein complexes. Bioinformatics, 2004. 20(1): p. 45−50.
163. Sternberg M.J., Gabb H.A., Jackson R.M., and Moont G. Protein-protein docking. Generation and filtering of complexes. Methods Mol. Biol, 2000. 143: p. 399−415.
164. Chaudhury S. and Gray JJ. Conformer selection and induced fit in flexible backbone protein-protein docking using computational and NMR ensembles. J. Mol. Biol, 2008. 381(4): p. 1068−1087.
165. Goodsell D.S., Morris G.M., and Olson A.J. Automated docking of flexible ligands: applications of AutoDock. J. Mol. Recognit., 1996. 9(1): p. 1−5.
166. Ewing T.J., Makino S., Skillman A.G., and Kuntz I.D. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput. Aided Mol. Des., 2001. 15(5): p. 411−428.
167. Rarey M., Kramer B., Lengauer T., and Klebe G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol., 1996.261(3): p. 470−489.
168. Halgren T.A., Murphy R.B., Friesner R.A., Beard H.S., Frye L.L., Pollard W.T., and Banks J.L. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J. Med. Chem., 2004.47(7): p. 1750−1759.
169. Verdonk M.L., Cole J.C., Hartshorn M.J., Murray C.W., and Taylor R.D. Improved protein-ligand docking using GOLD. Proteins, 2003. 52(4): p. 609−623.
170. Dominguez C., Boelens R., and Bonvin A.M. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J. Am. Chem. Soc., 2003. 125(7): p. 1731−1737.
171. Totrov M. and Abagyan R. Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins, 1997. Suppl 1: p. 215−220.
172. Wriggers W. and Birmanns S. Using situs for flexible and rigid-body fitting of multiresolution single-molecule data. J. Struct. Biol., 2001. 133(2−3): p. 193−202.
173. Sousa S.F., Fernandes P.A., and Ramos M.J. Protein-ligand docking: current status and future challenges. Proteins, 2006. 65(1): p. 15−26.
174. Skerra A. Engineered protein scaffolds for molecular recognition. J. Mol. Recognit., 2000. 13(4): p. 167−187.
175. Sidhu S.S., Li B., Chen Y., Fellouse F.A., Eigenbrot C., and Fuh G. Phage-displayed antibody libraries of synthetic heavy chain complementarity determining regions. J. Mol. Biol., 2004. 338(2): p. 299−310.
176. Bostrom J., Lee C.V., Haber L., and Fuh G. Improving antibody binding affinity and specificity for therapeutic development. Methods Mol. Biol., 2009. 525: p. 353−376, xiii.
177. Lee C.V., Liang W.C., Dennis M.S., Eigenbrot C., Sidhu S.S., and Fuh G. High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold. J. Mol. Biol., 2004. 340(5): p. 1073−1093.
178. Schier R., Balint R.F., McCall A., Apell G., Larrick J.W., and Marks J.D. Identification of functional and structural amino-acid residues by parsimonious mutagenesis. Gene, 1996. 169(2): p. 147−155.
179. Brorson K., Thompson C., Wei G., Krasnokutsky M., and Stein K.E. Mutational analysis of avidity and fine specificity of anti-levan antibodies. J Immunol, 1999. 163(12): p. 66 946 701.
180. Jackson T., Morris B.A., Martin A.C., Lewis D.F., and Sanders P.G. Molecular modelling and site-directed mutagenesis on a bovine anti-testosterone monoclonal antibody. Protein Eng., 1992. 5(4): p. 343−350.
181. Liu Y. and Kuhlman B. RosettaDesign server for protein design. Nucleic Acids Res., 2006. 34(Web Server issue): p. W235−238.
182. Yuan L., Kurek I., English J., and Keenan R. Laboratory-directed protein evolution. Microbiol. Mol. Biol. Rev., 2005. 69(3): p. 373−392.
183. Wells J.A. Additivity of mutational effects in proteins. Biochemistry, 1990. 29(37): p. 8509−8517.
184. Riechmann L. and Weill M. Phage display and selection of a site-directed randomized single-chain antibody Fv fragment for its affinity improvement. Biochemistry, 1993. 32(34): p. 8848−8855.
185. Foote J. and Winter G. Antibody framework residues affecting the conformation of the hypervariable loops. J. Mol. Biol., 1992. 224(2): p. 487−499.
186. Chen C., Roberts V.A., and Rittenberg M.B. Generation and analysis of random point mutations in an antibody CDR2 sequence: many mutated antibodies lose their ability to bind antigen. J. Exp. Med., 1992. 176(3): p. 855−866.
187. Chomczynski P. and Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem., 1987. 162(1): p. 156−159.
188. Chung C.T., Niemela S.L., and Miller R.H. One-step preparation of competent Escherichia coli: transformation and storage of bacterial cells in the same solution. Proc. Natl. Acad. Sci. U. S. A., 1989. 86(7): p. 2172−2175.
189. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 1970. 227(5259): p. 680−685.
190. Lowry O.H., Rosebrough N J., Farr A.L., and Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 1951. 193(1): p. 265−275.
191. Wibbenmeyer J.A., Xavier K.A., Smith-Gill S.J., and Willson R.C. Cloning, expression, and characterization of the Fab fragment of the anti-lysozyme antibody HyHEL-5. Biochim. Biophys. Acta, 1999. 1430(2): p. 191−202.
192. Frey A., Meckelein B., Externest D., and Schmidt M.A. A stable and highly sensitive 3,3', 5,5'-tetramethylbenzidine-based substrate reagent for enzyme-linked immunosorbent assays. J. Immunol. Methods, 2000. 233(1−2): p. 47−56.
193. Adamczyk M., Gebler J.C., and Wu J. Papain digestion of different mouse IgG subclasses as studied by electrospray mass spectrometry. J. Immunol. Methods, 2000. 237(1−2): p. 95 104.
194. Guerois R., Nielsen J.E., and Serrano L. Predicting changes in the stability of proteins and protein complexes: a study of more than 1000 mutations. J. Mol. Biol., 2002. 320(2): p. 369−387.
195. Saito R. and Tomita M. On negative selection against ATG triplets near start codons in eukaryotic and prokaryotic genomes. J. Mol. Evol., 1999. 48(2): p. 213−217.
196. Sharp A.J. and Slater R.J. Mung-Bean Nuclease 1 (EC 3.1.30.1). Methods Mol Biol, 1993. 16: p. 253−261.
197. Buchner J. and Rudolph R. Renaturation, purification and characterization of recombinant Fab-fragments produced in Escherichia coli. Biotechnology. (N. Y). 1991. 9(2): p. 157−162.
198. Mayer M. and Buchner J. Refolding of Inclusion Body Proteins, in Methods Mol. Med. 2004, Humana Press Inc. Totowa, NJ. p. 239−254.
199. Kiefhaber T., Rudolph R., Kohler H.H., and Buchner J. Protein aggregation in vitro and in vivo: a quantitative model of the kinetic competition between folding and aggregation. Biotechnology. (N. Y). 1991. 9(9): p. 825−829.
200. Schein C.H. and Noteborn M.H.M. Formation of soluble recombinant proteins in Escherichia coli is favored by lower growth temperature. Biotechnology, 1988. 6(291−294).
201. Lilie H., Schwarz E., and Rudolph R. Advances in refolding of proteins produced in E. coli. Curr. Opin. Biotechnol., 1998. 9(5): p. 497−501.
202. Arora D. and Khanna N. Method for increasing the yield of properly folded recombinant human gamma interferon from inclusion bodies. J. Biotechnol., 1996. 52(2): p. 127−133.
203. Buchner J., Pastan I., and Brinkmann U. A method for increasing the yield of properly folded recombinant fusion proteins: single-chain immunotoxins from renaturation of bacterial inclusion bodies. Anal. Biochem., 1992. 205(2): p. 263−270.
204. De Bernardez Clark E., Schwarz E., and Rudolph R. Inhibition of aggregation side reactions during in vitro protein folding. Methods Enzymol., 1999. 309: p. 217−236.
205. Chalmers J.J., Kim E., Telford J.N., Wong E.Y., Tacon W.C., Shuler M.L., and Wilson D.B. Effects of temperature on Escherichia coli overproducing beta-lactamase or human epidermal growth factor. Appl. Environ. Microbiol., 1990. 56(1): p. 104−111.
206. Lee M.H., Park T.I., Park Y.B., and Kwak J.W. Bacterial expression and in vitro refolding of a single-chain fv antibody specific for human plasma apolipoprotein B-100. Protein Expr. Purif., 2002. 25(1): p. 166−173.
207. Lei S.P., Lin H.C., Wang S.S., Callaway J., and Wilcox G. Characterization of the Erwinia carotovora pelB gene and its product pectate lyase. J. Bacteriol., 1987. 169(9): p. 43 794 383.
208. Pugsley A.P. and Possot O. The general secretory pathway of Klebsiella oxytoca: no evidence for relocalization or assembly of pilin-like PulG protein into a multiprotein complex. Mol. Microbiol., 1993. 10(3): p. 665−674.
209. Arbabi-Ghahroudi M., Tanha J., and MacKenzie R. Prokaryotic expression of antibodies. Cancer Metastasis Rev., 2005. 24(4): p. 501−519.
210. Lee N., Holtzapple C.K., and Stanker L.H. Cloning, expression and characterization of recombinant Fab antibodies against dioxin. J. Agric. Food Chem., 1998. 1(46): p. 33 813 388.
211. Maeda F., Nagatsuka Y., Ihara S., Aotsuka S., Ono Y., Inoko H., and Takekoshi M. Bacterial expression of a human recombinant monoclonal antibody fab fragment against hepatitis B surface antigen. J. Med. Virol, 1999. 58(4): p. 338−345.
212. Desogus A., Burioni R., Ingianni A., Bugli F., Pompei R., and Fadda G. Production and characterization of a human recombinant monoclonal Fab fragment specific for influenza A viruses. Clin. Diagn. Lab. Immunol, 2003.10(4): p. 680−685.
213. Diamandis E.P. and Christopoulos T.K. The biotin-(strept)avidin system: principles and applications in biotechnology. Clin. Chem., 1991. 37(5): p. 625−636.
214. Santala V. and Lamminmaki U. Production of a biotinylated single-chain antibody fragment in the cytoplasm of Escherichia coli. J. Immunol. Methods, 2004. 284(1−2): p. 165−175.
215. Smith G.P. and Petrenko V.A. Phage Display. Chem. Rev., 1997. 97(2): p. 391−410.
216. Benhar I. and Reiter Y. Phage display of single-chain antibody constructs. Curr Protoc Immunol, 2002. Chapter 10: p. Unit 10 19B.
217. Rojas G. Seleccion de fragmentos de anticuerpo especificos a partir de bibliotecas en fagos filamentosos. URL: http://elfosscientiae.cigb.edu.cu/PDFs/Muestras/chapterl 1 .pdf.
218. Yu H., Dong X.Y., and Sun Y. An alternating elution strategy for screening high affinity peptides from a phage display peptide library. Biochemical engineering journal, 2004. 18(3): p. 169−175.
219. Thomas W.D. and Smith G.P. The case for trypsin release of affinity-selected phages. Biotechniques, 2010. 49(3): p. 651−654.
220. Lee C.M., Iorno N., Sierro F., and Christ D. Selection of human antibody fragments by phage display. Nat Protoc, 2007. 2(11): p. 3001−3008.
221. Marks J.D. and Bradbury A. Selection of Human Antibodies from Phage Display Libraries. Antibody Engineering: Methods and Protocols, 2003. 248: p. 161.
222. Hoogenboom H.R. Designing and optimizing library selection strategies for generating high-affinity antibodies. Trends Biotechnol., 1997. 15(2): p. 62−70.